Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Starting soon · Phase 2

Conditions studied: Melanoma

In brief

This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma

Key facts

Study ID

NCT07517653

Run by

Shanghai Zhongshan Hospital

People needed

70

Starts

2026-04-01

Expected to finish

2028-12-30

Last updated by the study team

2026-04-08

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years and ≤ 75 years, regardless of sex.
• Histopathologically confirmed mucosal melanoma.
• Focal, lymph node metastatic, or oligometastatic mucosal melanoma assessed as completely resectable by multidisciplinary team (surgery/ENT/gynecology/colorectal, radiotherapy, oncology, imaging/pathology, etc.).
• ECOG Performance Status of 0 or 1.
• Life expectancy ≥ 12 weeks.

You may not qualify if…

• Prior treatment with PD-1/PD-L1 antibodies or anti-angiogenic agents.
• Ocular melanoma or melanoma of unknown primary site.
• History of immunodeficiency, acquired or congenital immune deficiency diseases, or organ transplantation.
• Pregnant or breastfeeding women.
• Abnormal coagulation function (APTT > 43 seconds or INR > 1.5 × ULN), or history of bleeding tendency or bleeding events (e.g., gastrointestinal bleeding, gastric ulcer bleeding) within 3 months before enrollment.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.